▁A 4.55859375
▁British 7.6015625
▁ph 7.2421875
arma 0.494384765625
ce 0.08258056640625
ut 0.0015897750854492188
ical 0.0004773139953613281
▁company 0.51025390625
▁has 1.33984375
▁reported 4.19921875
▁positive 3.666015625
▁results 0.380615234375
▁from 0.38818359375
▁its 1.953125
▁clin 2.388671875
ical 0.0020427703857421875
▁trial 0.446044921875
▁of 0.693359375
▁a 0.77197265625
▁cancer 4.703125
▁drug 0.78955078125
. 1.796875
▁However 5.2890625
, 0.10076904296875
▁anal 4.5234375
yst 0.00423431396484375
s 0.0152587890625
▁have 1.736328125
▁expressed 2.40625
▁ca 2.6796875
ution 0.0006771087646484375
, 2.388671875
▁warning 2.486328125
▁that 0.25244140625
▁there 3.51953125
▁is 0.9951171875
▁still 1.134765625
▁a 0.6474609375
▁long 0.4580078125
▁way 0.1396484375
▁to 0.0171051025390625
▁go 0.006458282470703125
▁before 0.356689453125
▁the 0.470703125
▁drug 0.83203125
▁can 1.126953125
▁be 0.244873046875
▁approved 1.7060546875
▁for 0.6376953125
▁use 0.515625
. 0.59619140625
<0x0A> 0.1663818359375
The 0.90234375
▁drug 1.1943359375
, 0.295654296875
▁developed 4.20703125
▁by 0.008636474609375
▁British 4.27734375
▁Bi 4.50390625
ote 0.007389068603515625
ch 0.1480712890625
, 2.08984375
▁is 0.69091796875
▁designed 1.58203125
▁to 0.003520965576171875
▁target 1.73046875
▁a 0.70068359375
▁specific 1.1171875
▁protein 1.173828125
▁that 0.62353515625
▁is 0.09405517578125
▁found 1.396484375
▁in 0.498291015625
▁many 1.537109375
▁types 0.481201171875
▁of 0.0013637542724609375
▁cancer 0.060516357421875
▁cells 0.76708984375
. 0.06170654296875
▁In 2.552734375
▁the 0.33056640625
▁clin 1.3271484375
ical 0.0003056526184082031
▁trial 0.0078125
, 0.004180908203125
▁the 0.278564453125
▁drug 0.02728271484375
▁was 0.17822265625
▁tested 2.583984375
▁on 0.1673583984375
▁patients 0.410400390625
▁with 0.046142578125
▁advanced 0.5078125
- 3.08203125
stage 0.0030651092529296875
▁can 2.5703125
cers 0.00042366981506347656
, 1.10546875
▁including 1.0615234375
▁pan 2.39453125
cre 6.389617919921875e-05
atic 0.007549285888671875
▁cancer 1.4208984375
, 0.748046875
▁breast 3.033203125
▁cancer 0.0028247833251953125
, 0.2288818359375
▁and 0.0631103515625
▁le 5.125
uk 0.86669921875
emia 0.00566864013671875
. 0.0026416778564453125
<0x0A> 0.166015625
Acc 3.736328125
ording 6.818771362304688e-05
▁to 0.00014030933380126953
▁the 0.134521484375
▁company 0.6455078125
, 0.10638427734375
▁the 0.00949859619140625
▁drug 0.431396484375
▁showed 1.888671875
▁prom 0.5849609375
ising 8.535385131835938e-05
▁results 0.0079803466796875
, 1.2568359375
▁with 0.046478271484375
▁some 1.328125
▁patients 0.0048370361328125
▁experien 0.44921875
cing 2.0623207092285156e-05
▁a 1.0361328125
▁reduction 2.275390625
▁in 0.0009403228759765625
▁the 1.505859375
▁size 0.01015472412109375
▁of 0.00634002685546875
▁their 0.00431060791015625
▁tum 0.042022705078125
ors 0.0330810546875
▁and 0.6162109375
▁surv 11.2578125
iving 0.56591796875
▁longer 0.2486572265625
▁than 0.140869140625
▁expected 1.224609375
. 0.005336761474609375
▁However 0.422607421875
, 4.756450653076172e-05
▁the 0.63525390625
▁trial 1.3828125
▁was 0.2161865234375
▁relatively 2.25390625
▁small 0.0004603862762451172
, 0.387451171875
▁with 0.70166015625
▁only 0.218994140625
▁ 0.208251953125
3 1.70703125
0 0.71728515625
▁patients 0.03912353515625
▁taking 1.08203125
▁part 0.0247344970703125
, 0.54248046875
▁and 0.0450439453125
▁the 0.8193359375
▁drug 3.078125
▁has 1.763671875
▁yet 1.1943359375
▁to 5.078315734863281e-05
▁be 0.06878662109375
▁tested 0.3857421875
▁in 2.060546875
▁a 1.92578125
▁larger 0.09381103515625
- 4.20703125
scale 0.00021004676818847656
▁trial 0.90576171875
. 0.05126953125
<0x0A> 0.00835418701171875
Anal 1.0361328125
yst 0.004283905029296875
s 0.00043702125549316406
▁have 0.1295166015625
▁war 0.68798828125
ned 1.5139579772949219e-05
▁against 5.24609375
▁getting 0.7294921875
▁too 0.10711669921875
▁excited 0.0977783203125
▁about 0.12139892578125
▁the 0.00542449951171875
▁results 0.51513671875
, 0.1776123046875
▁saying 2.138671875
▁that 0.007099151611328125
▁it 3.384765625
▁is 0.039764404296875
▁still 0.8720703125
▁too 0.437255859375
▁early 0.0247344970703125
▁in 10.5
▁the 0.01397705078125
▁drug 1.099609375
▁development 1.3603515625
▁process 0.0079803466796875
▁to 0.27783203125
▁draw 2.18359375
▁any 0.7529296875
▁firm 0.497314453125
▁conclus 8.440017700195312e-05
ions 8.344650268554688e-06
. 0.0384521484375
▁They 0.9580078125
▁c 7.10546875
ite 1.2568359375
▁the 0.350830078125
▁fact 1.515625
▁that 0.00025177001953125
▁many 3.32421875
▁prom 2.818359375
ising 5.602836608886719e-06
▁cancer 1.2021484375
▁dru 0.1138916015625
gs 1.1920928955078125e-07
▁have 0.10418701171875
▁failed 0.0897216796875
▁in 0.3291015625
▁later 0.96826171875
- 1.56640625
stage 0.001621246337890625
▁tri 0.521484375
als 1.0728836059570312e-06
, 0.970703125
▁either 4.33984375
▁because 0.62646484375
▁they 0.132568359375
▁did 2.23828125
▁not 2.682209014892578e-05
▁work 0.2186279296875
▁as 0.09075927734375
▁well 0.29541015625
▁as 0.0226287841796875
▁expected 0.7275390625
▁or 0.11590576171875
▁because 0.048187255859375
▁they 0.04888916015625
▁had 0.7353515625
▁un 0.93359375
antic 3.90625
ip 1.8715858459472656e-05
ated 1.6570091247558594e-05
▁side 0.01154327392578125
▁effects 0.002231597900390625
. 0.0082550048828125
<0x0A> 0.007122039794921875
In 2.923828125
▁addition 0.587890625
, 0.034210205078125
▁the 0.84033203125
▁analysis 5.60546875
▁of 0.97412109375
▁the 0.580078125
▁trial 2.083984375
▁data 1.2705078125
▁has 1.337890625
▁not 1.2197265625
▁yet 0.7236328125
▁been 0.017852783203125
▁peer 1.5625
- 0.04058837890625
review 0.00027251243591308594
ed 0.00026702880859375
▁or 2.49609375
▁published 0.0599365234375
▁in 0.07623291015625
▁a 0.004924774169921875
▁medical 1.96484375
▁journal 0.000324249267578125
, 0.0997314453125
▁which 0.57568359375
▁means 0.65673828125
▁that 0.02435302734375
▁it 1.26953125
▁has 0.744140625
▁not 0.0179443359375
▁been 0.4677734375
▁subject 0.441162109375
▁to 0.6181640625
▁independent 2.927734375
▁scr 0.08074951171875
ut 8.702278137207031e-06
iny 0.00021696090698242188
▁from 2.986328125
▁other 0.2391357421875
▁exper 0.243408203125
ts 5.328655242919922e-05
▁in 0.044769287109375
▁the 0.00011944770812988281
▁field 0.0003349781036376953
. 0.003040313720703125
<0x0A> 0.32568359375
Des 0.59326171875
p 6.556510925292969e-05
ite 2.8133392333984375e-05
▁these 0.1905517578125
▁cave 1.0478515625
ats 6.92605972290039e-05
, 0.00033855438232421875
▁the 0.406005859375
▁news 1.87109375
▁of 0.78564453125
▁the 0.23388671875
▁positive 0.69970703125
▁trial 0.6337890625
▁results 0.025787353515625
▁has 0.2032470703125
▁led 5.26171875
▁to 0.0250701904296875
▁a 1.564453125
▁sur 0.5087890625
ge 4.172325134277344e-05
▁in 0.0259246826171875
▁British 3.03125
▁Bi 0.01107025146484375
ote 0.00040721893310546875
ch 0.0023956298828125
' 1.505859375
s 0.00029087066650390625
▁share 0.303466796875
▁price 0.01151275634765625
, 0.176025390625
▁as 3.486328125
▁invest 0.02490234375
ors 0.00013577938079833984
▁hope 1.8076171875
▁that 0.036773681640625
▁the 0.021209716796875
▁drug 0.1634521484375
▁will 1.5361328125
▁prove 2.458984375
▁to 0.1490478515625
▁be 0.003932952880859375
▁a 0.177001953125
▁break 1.3515625
through 1.800060272216797e-05
▁in 0.5517578125
▁the 0.1824951171875
▁fight 0.28466796875
▁against 1.9311904907226562e-05
▁cancer 0.000759124755859375
. 0.00189971923828125
<0x0A> 0.4892578125
The 1.447265625
▁company 0.346435546875
▁has 0.654296875
▁said 0.58544921875
▁that 0.007602691650390625
▁it 0.0147857666015625
▁plans 0.284912109375
▁to 0.0001188516616821289
▁continue 2.234375
▁testing 1.935546875
▁the 0.0024967193603515625
▁drug 0.0005459785461425781
▁in 0.0367431640625
▁further 4.5703125
▁tri 1.08984375
als 7.152557373046875e-07
, 0.67236328125
▁including 4.1875
▁a 1.0947265625
▁larger 0.1654052734375
- 0.58984375
scale 0.0001577138900756836
▁phase 3.216796875
▁II 1.9052734375
▁trial 0.12225341796875
▁that 1.1884765625
▁will 1.6708984375
▁involve 1.2373046875
▁several 2.41015625
▁hundred 0.095947265625
▁patients 0.0136260986328125
. 0.04754638671875
<0x0A> 2.916015625
If 1.7998046875
▁the 0.1470947265625
▁drug 0.2415771484375
▁continues 2.318359375
▁to 2.47955322265625e-05
▁show 0.08074951171875
▁prom 0.329833984375
ising 2.7179718017578125e-05
▁results 0.002689361572265625
, 1.548828125
▁it 0.2027587890625
▁could 0.11944580078125
▁offer 5.78515625
▁a 0.76904296875
▁new 0.2496337890625
▁treatment 0.546875
▁option 0.0007219314575195312
▁for 0.0022678375244140625
▁patients 0.37109375
▁with 0.0107421875
▁advanced 0.2451171875
- 0.057342529296875
stage 0.00028204917907714844
▁can 0.1419677734375
cers 3.600120544433594e-05
▁who 1.3271484375
▁currently 1.19140625
▁have 0.0022411346435546875
▁limited 1.404296875
▁options 0.295166015625
. 1.173828125
▁However 0.61083984375
, 3.540515899658203e-05
▁it 0.45703125
' 4.92578125
s 4.5180320739746094e-05
▁important 0.08013916015625
▁to 0.03778076171875
▁note 1.8896484375
▁that 0.0007710456848144531
▁it 2.4765625
▁will 1.1640625
▁be 2.5859375
▁several 0.9052734375
▁more 3.333984375
▁years 0.0003666877746582031
▁before 0.018707275390625
▁the 0.07977294921875
▁drug 0.00463104248046875
▁is 0.418212890625
▁likely 2.224609375
▁to 0.0003781318664550781
▁be 0.1817626953125
▁approved 0.241943359375
▁for 0.0211944580078125
▁use 0.04473876953125
, 1.3759765625
▁assuming 7.05078125
▁that 1.4970703125
▁it 0.52880859375
▁continues 0.78515625
▁to 0.0005707740783691406
▁show 0.212890625
▁positive 0.666015625
▁results 0.01512908935546875
▁in 0.11651611328125
▁later 2.662109375
- 0.1636962890625
stage 0.0009055137634277344
▁tri 0.052093505859375
als 2.2649765014648438e-06
. 0.0213775634765625
<0x0A> 0.223876953125
In 0.80029296875
▁the 0.410400390625
▁meant 0.01134490966796875
ime 3.6954879760742188e-06
, 3.361701965332031e-05
▁patients 1.166015625
▁with 0.383056640625
▁cancer 1.6552734375
▁will 1.15234375
▁continue 0.254150390625
▁to 0.0010852813720703125
▁rely 0.2005615234375
▁on 0.0029048919677734375
▁existing 0.37646484375
▁treat 0.2030029296875
ments 8.106231689453125e-06
, 0.13330078125
▁such 1.9580078125
▁as 2.8252601623535156e-05
▁chem 0.326171875
other 4.363059997558594e-05
apy 2.5033950805664062e-06
▁and 0.48681640625
▁radiation 0.6845703125
▁ther 0.0772705078125
apy 2.0503997802734375e-05
, 0.030548095703125
▁which 0.37158203125
▁can 0.60107421875
▁be 0.369873046875
▁effective 0.497802734375
▁but 0.53466796875
▁also 0.65966796875
▁have 0.96484375
▁significant 0.16748046875
▁side 0.0142669677734375
▁effects 0.00023365020751953125
. 0.040130615234375
<0x0A> 0.465087890625
The 1.9384765625
▁news 1.2021484375
▁of 0.047332763671875
▁the 0.14697265625
▁positive 0.1883544921875
▁trial 0.311279296875
▁results 0.00238800048828125
▁also 5.6953125
▁highlight 0.304931640625
s 0.001552581787109375
▁the 0.0028514862060546875
▁on 1.1875
going 0.00029397010803222656
▁efforts 2.390625
▁to 0.5595703125
▁develop 0.11279296875
▁new 0.0194854736328125
▁and 2.447265625
▁better 1.724609375
▁treat 0.320556640625
ments 1.0371208190917969e-05
▁for 0.00016605854034423828
▁cancer 0.004863739013671875
, 0.62744140625
▁a 2.470703125
▁disease 0.2047119140625
▁that 0.00225830078125
▁affect 1.0888671875
s 2.7894973754882812e-05
▁millions 0.01479339599609375
▁of 0.00031638145446777344
▁people 0.0002970695495605469
▁around 0.57080078125
▁the 2.0503997802734375e-05
▁world 0.0026397705078125
. 1.166015625
▁While 0.85546875
▁progress 2.880859375
▁has 0.122802734375
▁certainly 9.828125
▁been 1.71661376953125e-05
▁made 5.054473876953125e-05
▁in 0.1846923828125
▁recent 0.0648193359375
▁years 0.031646728515625
, 0.00550079345703125
▁as 7.66015625
▁seen 2.583984375
▁in 1.580078125
▁the 0.059906005859375
▁development 0.259521484375
▁of 0.004573822021484375
▁new 2.220703125
▁imm 0.7998046875
un 0.013031005859375
other 4.982948303222656e-05
apy 0.69580078125
▁dru 0.451171875
gs 9.5367431640625e-07
▁and 1.0751953125
▁other 1.9150390625
▁target 0.73828125
ed 0.00012183189392089844
▁ther 0.60791015625
ap 0.0004181861877441406
ies 3.6954879760742188e-06
, 0.01349639892578125
▁there 0.12646484375
▁is 0.024383544921875
▁still 0.03204345703125
▁much 1.2783203125
▁work 0.09075927734375
▁to 0.0146636962890625
▁be 0.00550079345703125
▁done 1.633167266845703e-05
▁to 1.13671875
▁improve 0.250732421875
▁out 0.8076171875
comes 1.0728836059570312e-05
▁for 0.052459716796875
▁cancer 1.052734375
▁patients 6.92605972290039e-05
. 0.054412841796875
<0x0A> 0.1658935546875
As 2.05859375
▁the 1.4794921875
▁development 3.626953125
▁of 0.07159423828125
▁new 0.365234375
▁cancer 0.381103515625
▁dru 0.454833984375
gs 1.0728836059570312e-06
▁continues 0.031280517578125
, 0.01328277587890625
▁it 0.05279541015625
' 0.76611328125
s 2.3126602172851562e-05
▁important 0.1224365234375
▁for 0.398681640625
▁patients 0.13623046875
▁and 0.35205078125
▁their 0.1011962890625
▁families 0.1759033203125
▁to 0.0011692047119140625
▁stay 0.64306640625
▁informed 0.0244293212890625
▁about 0.3046875
▁the 0.06298828125
▁latest 0.0190887451171875
▁research 0.66650390625
▁and 0.032135009765625
▁to 1.0390625
▁work 0.446044921875
▁closely 0.9384765625
▁with 5.7220458984375e-06
▁their 0.0010700225830078125
▁health 0.05438232421875
care 0.0133209228515625
▁prov 0.32080078125
iders 2.9087066650390625e-05
▁to 0.00843048095703125
▁explore 5.29296875
▁all 0.01102447509765625
▁available 0.361328125
▁treatment 0.067626953125
▁options 1.7523765563964844e-05
. 0.051605224609375
<0x0A> 0.75341796875
U 4.19921875
lt 0.1129150390625
imately 0.0015201568603515625
, 4.017353057861328e-05
▁the 0.2056884765625
▁hope 2.275390625
▁is 0.00527191162109375
▁that 0.000835418701171875
▁new 1.5771484375
▁cancer 1.8125
▁dru 0.2274169921875
gs 5.960464477539062e-07
▁like 0.45947265625
▁the 0.251953125
▁one 0.0216522216796875
▁being 0.428466796875
▁developed 0.1361083984375
▁by 0.0009026527404785156
▁British 0.0007915496826171875
▁Bi 0.00283050537109375
ote 0.00016021728515625
ch 0.0012807846069335938
▁will 0.1080322265625
▁prove 6.03125
▁to 0.004711151123046875
▁be 0.002521514892578125
▁safe 3.236328125
▁and 0.06683349609375
▁effective 0.00046253204345703125
▁treat 2.9765625
ments 1.6570091247558594e-05
▁that 0.1402587890625
▁can 0.11700439453125
▁improve 1.982421875
▁the 1.0234375
▁lives 0.2227783203125
▁of 0.002338409423828125
▁millions 4.48046875
▁of 0.00042366981506347656
▁people 0.109619140625
▁around 0.80322265625
▁the 9.334087371826172e-05
▁world 0.003353118896484375
. 0.1497802734375
▁But 6.02734375
▁until 1.296875
▁then 1.4443359375
, 0.0001875162124633789
▁ca 8.8125
ution 2.5272369384765625e-05
▁is 0.95263671875
▁war 0.433349609375
r 0.00019693374633789062
anted 0.00016760826110839844
, 0.5
▁and 0.203369140625
▁continued 3.958984375
▁research 0.58056640625
▁and 0.2498779296875
▁development 1.0341796875
▁are 1.1943359375
▁cru 3.8125
cial 0.0004329681396484375
. 2.625
